How Ethics Committees Ensure Ongoing Oversight During Clinical Trials

Introduction: Ethical Review Doesn’t End with Approval

Ethical approval of a clinical trial is not a one-time event. Once a study begins, ethics committees (also known as Institutional Review Boards or IRBs) are obligated to provide continuous oversight to safeguard participants’ rights, safety, and well-being throughout the entire trial lifecycle. Regulatory bodies like ICH-GCP, FDA, EMA, and CDSCO mandate that ethical review continues in real-time as new information becomes available, such as safety concerns, protocol amendments, or deviations.

This ongoing process ensures that risks remain acceptable, consent procedures stay relevant, and researchers remain accountable. This article outlines the essential components and best practices of continuous ethics oversight in clinical research.

1. The Regulatory Basis for Continuing Ethics Review

Globally recognized standards mandate continuous ethical monitoring. For example:

• ICH E6 (R2) GCP: Section 3.1 outlines that an EC must conduct continuing review at intervals appropriate to the degree of risk.
• FDA 21 CFR 56.109(f): Requires review at least annually, and more often for high-risk studies.
• EU Clinical Trials Regulation (EU CTR 536/2014): Incorporates ongoing safety updates and amendment approvals.
• Indian NDCT Rules, 2019: Mandates continued EC review and SAE oversight during the study.

These frameworks form the backbone of dynamic oversight, shifting ethics from a one-time checkpoint to an ongoing compliance commitment.

2. Scheduled Continuing Reviews: Annual and Interim

Most Ethics Committees conduct formal continuing reviews either annually or based on study risk profile. At these intervals, investigators submit an “Annual Progress Report” (APR) or “Continuing Review Application” (CRA) covering:

• Recruitment status and demographic summary
• List of adverse events (AEs), serious AEs (SAEs), and SUSARs
• Summary of protocol deviations and corrective actions
• Amendments and re-consents issued
• Ongoing risk-benefit assessment

Ethics Committees may request additional documentation such as DSMB reports or audit findings during review.

3. Protocol Amendments: Ethics Review Before Implementation

Changes to the protocol—whether administrative, scientific, or safety-related—must be submitted to the EC before implementation. Examples include:

• Eligibility criteria changes
• Dose modification or route of administration
• Extension of study duration
• Changes in recruitment or ICF materials

Most regulatory frameworks prohibit initiating these changes without EC review and approval, unless immediate implementation is necessary to eliminate apparent hazards.

4. Ongoing Review of Informed Consent and Re-Consent

Informed consent is not static. Continuous ethics oversight includes monitoring changes that require re-consenting participants. These may arise from:

• New risk information (e.g., post-marketing AE reports)
• Protocol changes that affect participant expectations
• Revised compensation structures or visit schedules

The EC ensures revised ICFs are appropriately translated, approved, and implemented with documentation of participant re-consent.

5. SAE Reporting and Ethics Committee Monitoring

SAEs and SUSARs must be reported to the EC in accordance with regulatory timelines. For example:

The EC evaluates these reports to determine if the study’s risk profile has changed and whether participant safety remains acceptable.

6. Ethics Oversight of Protocol Deviations and Noncompliance

Protocol deviations are inevitable in long studies, but must be logged, reported, and reviewed by the EC. Examples include:

• Missed visits or lab assessments
• Improper consent procedures
• Enrollment of ineligible subjects

Recurring deviations may trigger EC-mandated corrective actions, site re-training, or even study suspension.

7. Site Monitoring Reports and Ethics Audits

ECs may request periodic monitoring reports from the sponsor/CRO or perform their own site visits to ensure compliance. Key checkpoints include:

• Proper ICF storage and versioning
• Trial master file (TMF) updates
• Adverse event follow-up documentation
• Protocol adherence logs

Independent EC audits are more common in high-risk trials or those involving vulnerable populations.

8. Oversight of Data Monitoring Committees (DMC/DSMB)

For blinded or large-scale trials, ECs often review Data Monitoring Committee (DMC or DSMB) charters and reports to assess interim safety. They may evaluate:

• Unblinded safety signals
• Early stopping criteria
• Protocol continuation recommendations

The EC may even require submission of DMC minutes for high-risk studies (e.g., oncology, gene therapy).

9. External Factors Triggering EC Re-review

Even beyond sponsor-initiated updates, the EC must remain vigilant to external developments that may impact the ethical viability of a trial. Examples include:

• New safety data from global studies
• Drug withdrawal by another regulatory agency
• Updated treatment guidelines
• Negative media coverage affecting public perception

Ethics Committees must evaluate whether continued trial conduct remains justified in such scenarios.

10. Documentation and Archival of Oversight Activities

Regulations require that all ethical oversight activities be properly documented and archived. This includes:

• Minutes of continuing review meetings
• Approval letters for amendments and annual reviews
• SAE communications and decisions
• Re-consent tracking logs

This documentation is subject to audit by regulatory agencies and must be retained for a minimum duration (e.g., 5 years post-trial in EU, 3 years in US).

Conclusion: Making Ethics Oversight an Active Process

Continuous ethics oversight ensures that the dynamic nature of clinical trials is matched by an equally responsive ethical review process. From monitoring SAEs and amendments to tracking re-consents and deviations, ethics committees play a crucial role in upholding the rights and safety of participants throughout the trial lifecycle.

By adopting proactive review schedules, digital reporting systems, and training for real-time risk assessment, ECs can move from passive reviewers to engaged guardians of participant welfare.

Best Practices for Submitting Protocol Amendments to the Ethics Committee

Clinical trials often evolve over time, requiring changes to the study protocol. These changes, whether minor or significant, must be submitted to the Ethics Committee (EC) or Institutional Review Board (IRB) for review and approval before implementation. Improper handling of protocol amendments can lead to compliance breaches, trial delays, or regulatory sanctions. This tutorial outlines the best practices for preparing and submitting protocol amendments to an EC in compliance with ICH-GCP and regulatory expectations.

When is a Protocol Amendment Required?

A protocol amendment is necessary when there is a modification to the originally approved clinical trial protocol. Amendments may include:

• Changes to inclusion/exclusion criteria
• Revised visit schedules or procedures
• Updated safety monitoring plans
• Addition or removal of investigational sites
• Change in the principal investigator
• Updates to the informed consent form (ICF)

As per USFDA and CDSCO guidance, these changes must not be implemented until approved by the relevant EC.

Types of Protocol Amendments:

• Substantial Amendments: Significant changes that may affect participant safety or data integrity
• Non-Substantial Amendments: Administrative or formatting changes that do not impact study conduct or risk-benefit assessment

Substantial amendments always require EC approval. Non-substantial changes may be communicated as per local SOPs but may not require formal approval.

Step-by-Step Process for Submitting Protocol Amendments:

1. Finalize the Amendment

• Ensure the sponsor has reviewed and authorized the changes
• Update protocol version and date (e.g., Version 2.0, dated 20-June-2025)
• Generate both “clean” and “tracked changes” versions

2. Prepare Supporting Documents

The submission package to the EC should include:

• Cover letter explaining the rationale for the amendment
• Revised protocol (clean and tracked)
• Summary of changes (tabular format preferred)
• Revised ICF if applicable (clean and tracked)
• Updated Investigator Brochure (IB) if impacted
• Amended CRFs or site instructions if applicable
• CV of new investigators or site details (if changed)
• EC amendment submission checklist or forms

Refer to standard pharma SOPs for amendment documentation formats and templates.

3. Draft a Clear Cover Letter

Your cover letter should include:

• Reference to the original protocol approval (EC letter date and reference number)
• A brief summary of what’s changing and why
• List of documents enclosed
• Contact details of the responsible person for queries

4. Highlight Regulatory Impact

If the amendment affects other regulatory submissions (e.g., DCGI/Health Canada), mention this in your submission.

Also assess how the amendment may impact stability studies or pharmacovigilance protocols.

5. Submit Within EC Timelines

• Check submission deadlines and meeting schedules
• Ensure all forms are correctly filled and signed
• Submit physical copies or digital formats as required

Common Pitfalls and How to Avoid Them:

• Missing Tracked Changes: Always include both clean and marked versions of documents
• Lack of Summary Table: ECs prefer tabular comparisons of old vs new content
• Outdated Version Numbers: Use updated protocol versions with consistent naming across documents
• Incomplete Forms: Cross-check against EC submission checklist
• Unjustified Changes: Explain scientific or safety rationale clearly

Timelines for EC Review of Amendments:

Depending on EC procedures and amendment complexity:

• Expedited review: 1–2 weeks
• Full board review: 3–6 weeks

Track submission date, follow-up queries, and approval receipt in the GMP documentation log.

After EC Approval:

• Update the Investigator Site File (ISF) with revised documents
• Train site staff on the changes
• Document training logs and acknowledgment forms
• Update regulatory submissions as required

Only after EC approval and training should the amended protocol be implemented at sites.

Maintaining an Amendment Tracker:

A centralized amendment tracker should include:

• Protocol version number and date
• Date of EC submission and approval
• Sites affected
• Document control IDs
• Status of implementation

This helps streamline audits and regulatory inspections. Maintain alignment with the validation master plan for documentation practices.

Conclusion:

Protocol amendments are a routine but critical part of clinical trial management. By following structured practices for amendment submission to Ethics Committees, sponsors and sites can ensure regulatory compliance, subject safety, and operational efficiency. Clear documentation, timely submissions, and robust communication are key to successfully navigating this important process.